Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood thinners in HHT: a risky balancing act under the microscope

NCT ID NCT05641142

Disease control Sponsor: University Hospital, Clermont-Ferrand Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study follows 100 adults with hereditary hemorrhagic telangiectasia (HHT) who start taking blood thinners (anticoagulants or antiplatelets). Researchers compare the three months before treatment to the first three months on treatment, tracking bleeding events, iron levels, and need for transfusions or IV iron. The goal is to see how well patients tolerate these medications in real-world conditions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
anticoagulant and/or antiplatelet therapy
What this could lead to
If successful, this could help doctors understand how to safely use blood thinners in people with HHT, reducing bleeding risks while managing clotting needs.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all HHT patients, and bleeding risks remain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with Rendu-Osler disease with an indication of antiplatelet and/or anticoagulant introduced for less than 3 months (inclusion period within 3 months of exposure) * Age \> 18 years old * Patient able to understand and agree to participate in the study * Affiliation to a social security system Exclusion Criteria: * Patient with an indication of antiplatelet and/or anticoagulant but for whom treatment has not been introduced or introduced for more than 3 months * Refusal to participate * Pregnant woman or who are breast feeding * Patients under maintenance of justice, wardship or legal guardianship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hereditary hemorrhagic telangiectasia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Epistaxis Hemorrhage hereditary hemorrhagic telangiectasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hereditary hemorrhagic telangiectasia Rendu osler disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    18 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AP-HP - Hôpital Ténon

    RECRUITING

    Paris, France

  • Assistance Publique - Hôpitaux de Marseille

    NOT_YET_RECRUITING

    Marseille, France

  • CHRU de Lille

    NOT_YET_RECRUITING

    Lille, France

  • CHRU de Strasbourg

    RECRUITING

    Strasbourg, France

  • CHU clermont-ferrand

    RECRUITING

    Clermont-Ferrand, France

  • CHU d'Angers

    RECRUITING

    Angers, France

  • CHU de Bordeaux

    RECRUITING

    Bordeaux, France

  • CHU de Caen Normandie

    RECRUITING

    Caen, France

  • CHU de Dijon

    RECRUITING

    Dijon, France

  • CHU de Montpellier

    RECRUITING

    Montpellier, France

  • CHU de Nancy

    RECRUITING

    Nancy, France

  • CHU de Nantes

    RECRUITING

    Nantes, France

  • CHU de Nice

    RECRUITING

    Nice, France

  • CHU de Poitiers

    NOT_YET_RECRUITING

    Poitiers, France

  • CHU de Rennes

    RECRUITING

    Rennes, France

  • CHU de Toulouse

    NOT_YET_RECRUITING

    Toulouse, France

  • Hospices Civiles de Lyon

    RECRUITING

    Lyon, France

  • Hôpital Ambroise Paré

    NOT_YET_RECRUITING

    Boulogne-Billancourt, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.